Sydney M Crago

The company received $100 million (USD) in this financing round from several investment partners as they generate new optogenetic therapeutics for blinding diseases.

Researchers at the Medical College of Georgia have shown in an animal model of retinopathy of prematurity that the small molecule K604 can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth.

Aviceda Therapeutics appoints Patrick Johnson, a strategic pharmaceutical executive, to its board of directors.

Eyetelligence will offer non-invasive point-of-care technology to diagnose a range of diseases, including diabetic retinopathy and age-related macular degeneration, with AI algorithmic retinal image analysis.

A study by Verana Health shows how de-identified real-world data (RWD) from electronic health records (EHRs) in medical registries can allow for a deeper understanding of data trends, patterns, or gaps.

This medical device is the first retinal eye-movement monitor for non-invasive, objective clinical assessments.

The study results show the potential of SREDs to treat progressive, chronic retina conditions including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).

The treatment is designed to slow the rate of degeneration of retinal cells, slowing the progression of geographic atrophy.

Researchers compile data from around 18,000 patients to provide a comprehensive understanding of the current state of nAMD treatment in the UK.

Researchers collaborate to study AMD through database of donor eye tissue to provide new data for study and future treatment targeting.

New clinic dedicated to treating pediatric uveitis opens in the UAE.

Researchers in Australia have identified genes that play a role in oxidative stress and aging in the macula.

Endogena Therapeutics Inc. has completed patient enrollment ahead of schedule with a cohort of 14 patients with RP due to any pathologic genetic mutation across 5 US sites.

A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks.

VLTR-557, Valitor's long-acting anti-VEGF biologic in development for durable wet age-related macular degeneration (AMD) treatment, showed that a single intravitreal (ITV) injection has potential to maintain clinical efficacy for more than six months.

Stoke Therapeutics, Inc. received authorization to initiate a UK-based Phase 1/2 study of STK-002, a treatment of autosomal dominant optic atrophy (ADOA), for which there is currently no approved treatments.

A team of researchers used gene expression, epigenetic, and gene regulation analyses to discover genes, pathways, and regulatory features relevant to age-related macular degeneration (AMD).

RetinAI announced their new partnership with Boehringer Ingelheim with the goal to improve patient outcomes in geographic atrophy (GA) by combining their respective expertise in artificial intelligence and retinal disease research.

Palatin Technologies, Inc. announced manuscript publication that summarizes data demonstrating the effects of PL8331 in two mouse models of retinal disease, experimental autoimmune uveoretinitis and diabetic retinopathy.

Complement Therapeutics GmbH secured financing to continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001, an AAV gene therapy for the treatment of GA secondary to dry-AMD.

Aviceda Therapeutics announced that the FDA has cleared the Investigational New Drug application for AVD-104, enabling the company to proceed with initiation of Phase 2 clinical trials.

Study results see brolucizumab as a viable treatment for patients with neovascular age-related macular degeneration (nAMD) refractory to other anti-VEGF drugs.

Kala Pharmaceuticals KPI-012 receives FDA Fast Track designation as treatment for PCED with potential to treat retinitis pigmentosa and Stargardt disease.

Research highlights the correlation between the gut microbiome and autoimmune disorders.

HuidaGene Therapeutics’ HG004 receives ODD for inherited retinal disease caused by RPE65 mutations.